{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:13:49Z","timestamp":1789384429095,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Regular monitoring of anti-malarial drug efficacy is vital for establishing rational malaria treatment guidelines and ensuring adequate treatment outcomes. This study aimed to synthesize the available evidence on the efficacy of artemether\u2013lumefantrine for the management of uncomplicated falciparum malaria in Ethiopia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. Relevant published studies were searched from the databases (PubMed, Google Scholar and Clinical trial registry) on published artemether\u2013lumefantrine therapeutic efficacy studies conducted in Ethiopia from 2004 to 2020. The retrieved studies were assessed for quality using the modified Newcastle Ottawa Scale for observational studies and modified Jadad scale for interventional studies. Risk of bias was also assessed by using ROBINS-I tool. OpenMeta-Analyst software was used for the statistical analysis. The review protocol is registered in PROSPERO, number CRD42020201859.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifteen studies (1523 participants) were included in the final analysis. The overall PCR-uncorrected pooled proportion of treatment success of artemether\u2013lumefantrine therapy for uncomplicated falciparum malaria was 98.4% (95%CI 97.6\u201399.1). A random-effects model was used because of considerable heterogeneity [\u03c7<jats:sup>2<\/jats:sup>\u2009=\u200920.48,<jats:italic>df<\/jats:italic>(14),<jats:italic>P<\/jats:italic>\u2009=\u20090.011 and I<jats:sup>2<\/jats:sup>\u2009=\u200931.65]. PCR-corrected pooled proportion of treatment success of artemether\u2013lumefantrine therapy was 98.7% (95% CI 97.7\u201399.6). A random-effects model was used [\u03c7<jats:sup>2<\/jats:sup>\u2009=\u20097.37,<jats:italic>df<\/jats:italic>(6),<jats:italic>P<\/jats:italic>\u2009=\u20090.287 and I<jats:sup>2<\/jats:sup>\u2009=\u200918.69]. Most studies included in the present review achieved a rapid reduction of fevers and parasitaemia between D0 and D3 of assessment. Adverse events were mostly mild and only two cases were reported as serious, but were not directly attributed to the drug.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The present meta-analysis suggests that artemether\u2013lumefantrine therapy is efficacious and safe in treating uncomplicated falciparum malaria in Ethiopia. However, owing to the high risk of bias in the included studies, strong conclusions cannot be drawn. Further high-quality RCTs assessing anti-malarial efficacy and safety should be performed to demonstrates strong evidence of changes in parasite sensitivity to artemether\u2013lumefantrine in Ethiopia.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12936-021-03745-8","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T10:03:39Z","timestamp":1620295419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy and safety of artemether\u2013lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ethiopia: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4501-4759","authenticated-orcid":false,"given":"Abdulhakim","family":"Abamecha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Yilma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wondimagegn","family":"Adissu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delenasaw","family":"Yewhalaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alemseged","family":"Abdissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"3745_CR1","volume-title":"National malaria elimination roadmap","author":"Federal Democratic Republic of Ethiopia Ministry of Health","year":"2016","unstructured":"Federal Democratic Republic of Ethiopia Ministry of Health. National malaria elimination roadmap. Addis Ababa: Federal Democratic Republic of Ethiopia Ministry of Health; 2016."},{"key":"3745_CR2","volume-title":"National malaria elimination strategic plan 2021\u20132025","author":"Federal Democratic Republic of Ethiopia Ministry of Health","year":"2020","unstructured":"Federal Democratic Republic of Ethiopia Ministry of Health. National malaria elimination strategic plan 2021\u20132025. Addis Ababa: Federal Democratic Republic of Ethiopia Ministry of Health; 2020."},{"key":"3745_CR3","volume-title":"Guidelines for the treatment of malaria","author":"WHO Global Malaria Programme","year":"2010","unstructured":"WHO Global Malaria Programme. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2010."},{"key":"3745_CR4","doi-asserted-by":"publisher","first-page":"e1001564","DOI":"10.1371\/annotation\/3db421e4-3e27-4442-8092-2ad1b778f371","volume":"10","author":"The WorldWide Antimalarial Resistance Network (WWARN) DP Study Group","year":"2013","unstructured":"The WorldWide Antimalarial Resistance Network (WWARN) DP Study Group. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med. 2013;10:e1001564.","journal-title":"PLoS Med."},{"key":"3745_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/0169-4758(96)10055-7","volume":"12","author":"NJ White","year":"1996","unstructured":"White NJ, Olliaro PL. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol Today. 1996;12:399\u2013401.","journal-title":"Parasitol Today"},{"key":"3745_CR6","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/S0140-6736(98)07367-X","volume":"353","author":"NJ White","year":"1999","unstructured":"White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al. Averting a malaria disaster. Lancet. 1999;353:1965\u20137.","journal-title":"Lancet"},{"key":"3745_CR7","volume-title":"Malaria diagnosis and treatment guidelines for health workers in Ethiopia","author":"Federal Democratic Republic of Ethiopia Ministry of Health","year":"2004","unstructured":"Federal Democratic Republic of Ethiopia Ministry of Health. Malaria diagnosis and treatment guidelines for health workers in Ethiopia. 2nd ed. Addis Ababa: Federal Democratic Republic of Ethiopia Ministry of Health; 2004.","edition":"2"},{"key":"3745_CR8","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1073\/pnas.1217452110","volume":"110","author":"N Klonis","year":"2013","unstructured":"Klonis N, Xie SC, McCaw JM, Crespo-Ortiz MP, Zaloumis SG, Simpson JA, et al. Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc Natl Acad Sci USA. 2013;110:5157\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 1","key":"3745_CR9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/1475-2875-8-S1-S3","volume":"8","author":"ZG Premji","year":"2009","unstructured":"Premji ZG, Kokwaro G, Mwai L, Nzila A, Efferth T, White N, et al. Coartem\u00ae: the journey to the clinic. Malar J. 2009;8(Suppl 1):S3.","journal-title":"Malar J"},{"key":"3745_CR10","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-018-06221-1","volume":"9","author":"JL Bridgford","year":"2018","unstructured":"Bridgford JL, Xie SC, Cobbold SA, Pasaje CFA, Herrmann S, Yang T, et al. Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome. Nat Commun. 2018;9:3801.","journal-title":"Nat Commun"},{"key":"3745_CR11","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.ijpara.2006.07.011","volume":"36","author":"J Golenser","year":"2006","unstructured":"Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE. Current perspectives on the mechanism of action of artemisinins. Int J Parasitol. 2006;36:1427\u201341.","journal-title":"Int J Parasitol"},{"key":"3745_CR12","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1038\/srep02513","volume":"3","author":"A Shandilya","year":"2013","unstructured":"Shandilya A, Chacko S, Jayaram B, Ghosh I. A plausible mechanism for the antimalarial activity of artemisinin: a computational approach. Sci Rep. 2013;3:2513.","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"3745_CR13","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/0035-9203(94)90471-5","volume":"88","author":"NJ White","year":"1994","unstructured":"White NJ. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans R Soc Trop Med Hyg. 1994;88(Suppl 1):S41\u20133.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3745_CR14","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/nature01813","volume":"424","author":"U Eckstein-Ludwig","year":"2003","unstructured":"Eckstein-Ludwig U, Webb RJ, Van Goethem IDA, East JM, Lee AG, Kimura M, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature. 2003;424:957\u201361.","journal-title":"Nature"},{"key":"3745_CR15","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"3745_CR16","volume-title":"National malaria guideline","author":"Federal Democratic Republic of Ethiopia Ministry of Health","year":"2012","unstructured":"Federal Democratic Republic of Ethiopia Ministry of Health. National malaria guideline. 3rd ed. Addis Ababa: Federal Democratic Republic of Ethiopia Ministry of Health; 2012.","edition":"3"},{"key":"3745_CR17","volume-title":"Malaria Operational Plan FY","author":"President\u2019s Malaria Initiative Ethiopia","year":"2020","unstructured":"President\u2019s Malaria Initiative Ethiopia. Malaria Operational Plan FY. Addis Ababa: President\u2019s malaria initiative Ethiopia; 2020."},{"key":"3745_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40249-017-0372-5","volume":"6","author":"MB Ayalew","year":"2017","unstructured":"Ayalew MB. Therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Ethiopia: a systematic review and meta-analysis. Infect Dis Poverty. 2017;6:157.","journal-title":"Infect Dis Poverty"},{"key":"3745_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12936-017-1922-9","volume":"16","author":"EA Gebreyohannes","year":"2017","unstructured":"Gebreyohannes EA, Bhagavathula AS, Seid MA, Tegegn HG. Anti-malarial treatment outcomes in Ethiopia: a systematic review and meta-analysis. Malar J. 2017;16:269.","journal-title":"Malar J"},{"key":"3745_CR20","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"key":"3745_CR21","doi-asserted-by":"crossref","unstructured":"Abamecha A, Yilma A, Addisu W, Yewhalaw D, Abdissa A. Monitoring of efficacy and safety of artemether-lumefantrine for treatment of uncomplicated P. falciparum malaria in Ethiopia: a systematic review and meta-analysis of the evidence. PROSPERO 2020 CRD42020201859.https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42020201859. Accessed 3 Aug 2020","DOI":"10.21203\/rs.3.rs-144492\/v1"},{"key":"3745_CR22","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane; 2019. www.training.cochrane.org\/handbook. Accessed 3 Mar 2020","DOI":"10.1002\/9781119536604"},{"key":"3745_CR23","unstructured":"The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions version 5.1.0 (2011); 2011. http:\/\/handbook.cochrane.org\/. Accessed 3 Mar 2020"},{"key":"3745_CR24","volume-title":"Malaria diagnosis and treatment guidelines for health workers","author":"Federal Ministry of Health of Ethiopia","year":"2004","unstructured":"Federal Ministry of Health of Ethiopia. Malaria diagnosis and treatment guidelines for health workers. Addis Ababa: Federal Ministry of Health of Ethiopia; 2004."},{"key":"3745_CR25","doi-asserted-by":"crossref","unstructured":"Lefebvre C, Manheimer E, Glanville J. Searching for studies. In: Higgins JPT, Greene S, Cochrane handbook for systematic reviews of interventions, Version 5.0. eds; 2008.","DOI":"10.1002\/9780470712184.ch6"},{"key":"3745_CR26","unstructured":"Wells GA,\u00a0Shea B,\u00a0O\u2019Connell D,\u00a0Peterson J,\u00a0Welch V,\u00a0Losos M,\u00a0Tugwell P.\u00a0The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses; 2012. http:\/\/www.ohrica\/programs\/clinical_epidemiology\/oxfordasp. Accessed 2 Dec 2020"},{"key":"3745_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1\u201312.","journal-title":"Control Clin Trials"},{"key":"3745_CR28","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"3745_CR29","unstructured":"Open-Meta-Analyst. http:\/\/www.cebm.brown.edu\/openmeta\/doc\/openMA_help.html#self. Accessed 3 Mar 2020"},{"key":"3745_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1471-2288-9-80","volume":"9","author":"BC Wallace","year":"2009","unstructured":"Wallace BC, Schmid CH, Lau J, Trikalinos TA. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol. 2009;9:80.","journal-title":"BMC Med Res Methodol"},{"key":"3745_CR31","unstructured":"Ryan R. Cochrane Consumers and Communication Review Group. Heterogeneity and subgroup analyses in Cochrane Consumers and Communication Group reviews: planning the analysis at protocol stage; 2016. http:\/\/cccrg.cochrane.org. Accessed 12 Feb 2019"},{"key":"3745_CR32","doi-asserted-by":"publisher","first-page":"e69930","DOI":"10.1371\/journal.pone.0069930","volume":"8","author":"E Kontopantelis","year":"2013","unstructured":"Kontopantelis E, Springate DA, Reeves D. A re-analysis of the Cochrane Library Data: the dangers of unobserved heterogeneity in meta-analyses. PLoS ONE. 2013;8:e69930.","journal-title":"PLoS ONE"},{"key":"3745_CR33","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"3745_CR34","first-page":"387","volume":"82","author":"D Jima","year":"2005","unstructured":"Jima D, Tesfaye G, Medhin A, Kebede A, Argaw D, Babaniyi O. Safety and efficacy of artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Ethiopia. East Afr Med J. 2005;82:387\u201390.","journal-title":"East Afr Med J"},{"key":"3745_CR35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12936-020-03307-4","volume":"19","author":"A Abamecha","year":"2020","unstructured":"Abamecha A, Yilma D, Addisu W, El-Abid H, Ibenthal A, Noedl H, et al. Therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Chewaka District, Ethiopia. Malar J. 2020;19:240.","journal-title":"Malar J"},{"key":"3745_CR36","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/1475-2875-11-240","volume":"11","author":"T Eshetu","year":"2012","unstructured":"Eshetu T, Abdo N, Bedru KH, Fekadu S, Wieser A, Pritsch M, et al. Open-label trial with artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria three years after its broad introduction in Jimma Zone, Ethiopia. Malar J. 2012;11:240.","journal-title":"Malar J"},{"key":"3745_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/1475-2875-10-209","volume":"10","author":"J Hwang","year":"2011","unstructured":"Hwang J, Alemayehu BH, Hoos D, Melaku Z, Tekleyohannes SG, Teshi T, et al. In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia. Malar J. 2011;10:209.","journal-title":"Malar J"},{"key":"3745_CR38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12936-015-0826-9","volume":"14","author":"SK Mekonnen","year":"2015","unstructured":"Mekonnen SK, Medhin G, Berhe N, Clouse RM, Aseffa A. Efficacy of artemether-lumefantrine therapy for the treatment of uncomplicated Plasmodium falciparum malaria in Southwestern Ethiopia. Malar J. 2015;14:317.","journal-title":"Malar J"},{"key":"3745_CR39","doi-asserted-by":"publisher","first-page":"e0154618","DOI":"10.1371\/journal.pone.0154618","volume":"11","author":"D Nega","year":"2016","unstructured":"Nega D, Assefa A, Mohamed H, Solomon H, Woyessa A, Assefa Y, et al. Therapeutic efficacy of artemether-lumefantrine (Coartem\u00ae) in treating uncomplicated P falciparum malaria in Metehara, Eastern Ethiopia: regulatory clinical study. PLoS ONE. 2016;11:e0154618.","journal-title":"PLoS ONE"},{"key":"3745_CR40","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12936-015-0775-3","volume":"14","author":"G Getnet","year":"2015","unstructured":"Getnet G, Fola AA, Alemu A, Getie S, Fuehrer HP, Noedl H. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Enfranze, north-west Ethiopia. Malar J. 2015;14:258.","journal-title":"Malar J"},{"key":"3745_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-3305-3-1","volume":"3","author":"A Assefa","year":"2010","unstructured":"Assefa A, Kassa M, Tadese G, Mohamed H, Animut A, Mengesha T. Therapeutic efficacy of artemether\/lumefantrine (Coartem\u00ae) against Plasmodium falciparum in Kersa, South West Ethiopia. Parasit Vectors. 2010;3:1.","journal-title":"Parasit Vectors"},{"key":"3745_CR42","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/TCRM.S127571","volume":"13","author":"T Deressa","year":"2017","unstructured":"Deressa T, Seid ME, Birhan W, Aleka Y, Tebeje BM. In vivo efficacy of artemether\u2013lumefantrine against uncomplicated Plasmodium falciparum malaria in Dembia District, northwest Ethiopia. Ther Clin Risk Manag. 2017;13:201\u20136.","journal-title":"Ther Clin Risk Manag"},{"key":"3745_CR43","first-page":"548710","volume":"2012","author":"G Kinfu","year":"2012","unstructured":"Kinfu G, Gebre-selassie S, Fikrie N. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Northern Ethiopia. Malar Res Treat. 2012;2012:548710.","journal-title":"Malar Res Treat"},{"key":"3745_CR44","doi-asserted-by":"publisher","first-page":"e0176004","DOI":"10.1371\/journal.pone.0176004","volume":"12","author":"M Teklemariam","year":"2017","unstructured":"Teklemariam M, Assefa A, Kassa M, Mohammed H, Mamo H. Therapeutic efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in a high-transmission area in northwest Ethiopia. PLoS ONE. 2017;12:e0176004.","journal-title":"PLoS ONE"},{"key":"3745_CR45","doi-asserted-by":"publisher","first-page":"492","DOI":"10.18203\/2319-2003.ijbcp20150026","volume":"4","author":"A Mulu","year":"2015","unstructured":"Mulu A, Geresu B, Beyene Y, Ademe M. Efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Northeast Ethiopia. Int J Basic Clin Pharmacol. 2015;4:492\u20136.","journal-title":"Int J Basic Clin Pharmacol"},{"key":"3745_CR46","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1051\/parasite\/2009162129","volume":"16","author":"T Kefyalew","year":"2009","unstructured":"Kefyalew T, Animut A, Tamene T, Jima D, Hailemariam A, Legesse M. Efficacy of six-dose regimen of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria, three years after its introduction into Ethiopia. Parasite. 2009;16:129\u201334.","journal-title":"Parasite"},{"key":"3745_CR47","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12936-015-0744-x","volume":"14","author":"YA Ebstie","year":"2015","unstructured":"Ebstie YA, Zeynudin A, Belachew T, Desalegn Z, Suleman S. Assessment of therapeutic efficacy and safety of artemether-lumefantrine (Coartem\u00ae) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia: an observational cohort study. Malar J. 2015;14:236.","journal-title":"Malar J"},{"key":"3745_CR48","first-page":"42","volume":"6","author":"ZZ Kanche","year":"2016","unstructured":"Kanche ZZ, Woticha EW, Gidebo KD. Therapeutic efficacy and safety of artemether\u2013lumefantrine (Coartem\u00ae) in uncomplicated Plasmodium falciparum malaria in Wolaita Zone, Southern Ethiopia. J Biol Agric Healthc. 2016;6:42\u20138.","journal-title":"J Biol Agric Healthc"},{"key":"3745_CR49","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2147\/TCRM.S113603","volume":"12","author":"F Wudneh","year":"2016","unstructured":"Wudneh F, Assefa A, Nega D, Mohammed H, Solomon H, Kebede T, et al. Open-label trial on efficacy of artemether\/lumefantrine against the uncomplicated Plasmodium falciparum malaria in Metema district, Northwestern Ethiopia. Ther Clin Risk Manag. 2016;12:1293\u2013300.","journal-title":"Ther Clin Risk Manag"},{"key":"3745_CR50","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12936-018-2265-x","volume":"17","author":"I Adam","year":"2018","unstructured":"Adam I, Ibrahim Y, Gasim GI. Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: a systematic review and meta-analysis. Malar J. 2018;17:110.","journal-title":"Malar J"},{"key":"3745_CR51","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/cid\/cir066","volume":"52","author":"BE Ngasala","year":"2011","unstructured":"Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D, et al. Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children < 5 years of age with acute uncomplicated Plasmodium falciparummalaria in rural Tanzania: a randomized trial. Clin Infect Dis. 2011;52:873\u201382.","journal-title":"Clin Infect Dis"},{"key":"3745_CR52","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1128\/AAC.04181-14","volume":"59","author":"MM Plucinski","year":"2015","unstructured":"Plucinski MM, Talundzic E, Morton L, Dimbu PR, Macaia AP, Fortes F, et al. Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in children in Zaire and U\u00edge Provinces, Angola. Antimicrob Agents Chemother. 2015;59:437\u201343.","journal-title":"Antimicrob Agents Chemother"},{"key":"3745_CR53","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/ncomms6606","volume":"5","author":"LC Okell","year":"2014","unstructured":"Okell LC, Cairns M, Griffin JT, Ferguson NM, Tarning J, Jagoe G, et al. Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. Nat Commun. 2014;5:5606.","journal-title":"Nat Commun"},{"key":"3745_CR54","volume-title":"World malaria report","author":"WHO","year":"2018","unstructured":"WHO. World malaria report. Geneva: World Health Organization; 2018."},{"key":"3745_CR55","volume-title":"Policy Brief on single-dose primaquine as a gametocytocide in Plasmodium falciparum malaria","author":"WHO","year":"2015","unstructured":"WHO. Policy Brief on single-dose primaquine as a gametocytocide in Plasmodium falciparum malaria. Geneva: World Health Organization; 2015."},{"key":"3745_CR56","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12916-015-0445-x","volume":"13","author":"P Dahal","year":"2015","unstructured":"WWARN Artemisinin based Combination Therapy (ACT) Africa Baseline Study Group, Dahal P, Dalessandro U, Dorsey G, Guerin PJ, Nsanzabana C, et al. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. BMC Med. 2015;13:212.","journal-title":"BMC Med"},{"key":"3745_CR57","volume-title":"Global plan for artemisinin resistance containment (GPARC)","author":"WHO","year":"2011","unstructured":"WHO. Global plan for artemisinin resistance containment (GPARC). Geneva: World Health Organization; 2011."},{"key":"3745_CR58","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12936-015-0649-8","volume":"14","author":"A Shayo","year":"2015","unstructured":"Shayo A, Buza J, Ishengoma DS. Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania. Malar J. 2015;14:135.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03745-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03745-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03745-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T09:29:33Z","timestamp":1699003773000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03745-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3745"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03745-8","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"6 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PRISMA guideline [] (Additional file) recommendations were used and strictly followed to carry out this systematic review and meta-analysis. Ethical approval is not recommended and was not needed since it is a systematic review and meta-analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have given their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}